Objectives: Disease prognosis of endometrial carcinoma varies significantly depending on the International Federation of Gynecology and Obstetrics (FIGO) grade, extent of the myometrial invasion, and tumor type. However, assessment of these tumor characteristics can be difficult and subjective. Therefore, the interobserver variability would play a major role in the credibility of the consensus guidelines. Methods: Institutional review board approval was obtained. Five pathologists independently evaluated one representative section of a total of 90 cases of uterine carcinoma for tumor FIGO grade, myometrial invasion, and tumor subtypes. The 90 cases included 73 endometrioid adenocarcinoma, two mixed endometrioid and serous carcinoma, seven carcinosarcoma, six serous carcinoma, and two clear cell carcinoma. Results: For the FIGO grades, only 22/90 cases were agreed on by all five pathologists, 49/90 cases were agreed on by 4/5 pathologists, and 88/90 cases were agreed on by 3/5 pathologists. If the FIGO grades 1 and 2 were together denoted as low grade, and FIGO 3 denoted as high grade, all five pathologists agreed on 70/90 cases. For myometrial invasion (<1/2 vs >1/2), all five pathologists agreed on 65/75 cases, and 4/5 pathologists agreed on 72/75 cases. For carcinoma subtypes, none of the 10 cases of clear cell or serous carcinoma was agreed by all five pathologists based on morphology. Conclusion: Two-tier FIGO grading (low grade vs high grade) appears better than the three-tier classification system, but the group consensus diagnosis seems to be the best system for FIGO grading. Evaluation of myometrial invasion (<1/2 vs >1/2) appears to be very reliable among the practicing pathologists. Identification of the serous or clear cell component based on pure morphology is not reliable, and immunohistochemistry should be routinely applied. Background: Mammary analogue secretory carcinoma of the salivary gland (MASC) is a newly identified entity genetically defined by harboring an unique cytogenetic features of t (12,15) (p13; q25) translocation with ETV6-NTRK3 fusion protein. This low-grade salivary gland tumor mimics salivary acinic cell carcinoma or low-grade adenocarcinoma morphologically and was not recognized until recently. Two cases of mammary analogue secretory carcinoma of the salivary gland have been recently identified in our institution, which was confirmed by ETV6 translocation fluorescence in situ hybridization study. To have a better understanding of the incidence and characteristics of this rare entity in our institution, we reviewed the cases with the diagnosis of acinic cell carcinoma or low-grade adenocarcinoma of salivary gland tumor from our archives. Methods: A total of 37 cases of salivary gland tumor with the diagnosis of salivary acinic cell carcinoma or lowgrade adenocarcinoma were retrieved from our archives from between 2000 and 2016. The morphology of all the cases was reviewed. Microscopically, three cases are composed of circumscribed nodules with bland neoplastic epithelial cells arranged in microcytic, tubular, and solid growth pattern, characteristic for the description of typical MASC. All the cases were subjected to fluorescence in situ hybridization (FISH) study using dual-color breakapart rearrangement probes for ETV6. When two separate signals (a red and a green) were observed, ETV6 was considered split. The cutoff value for the ETV6 split was 10%. Seven cases were eliminated from the study due to technical difficulties for getting the signal. Result: A total of 30 cases with diagnosis of acinic cell carcinoma or low grade adenocarcinoma all show negativity for ETV6 breakapart FISH study. This includes 21 cases of acinic cell carcinoma, seven cases of polymorphous low-grade adenocarcinoma, and two cases of low-grade salivary gland adenocarcinoma. This result could be due to several possibilities. First, there might be some cases with possible positivity for ETV6 translocation within the seven cases with technical difficulties for getting the signal. Second, according to the literature, there is additional translocation in MASC involving ETV6, which may not be positive with the ETV6 FISH assay utilized in our study. A third possibility is that MASC is a rare tumor in our institution because of referral patterns. Conclusion: Our result shows that MASC is a very rare low-grade salivary gland tumor in our institution. Our study also confirms that true acinic cell carcinoma does not harbor ETV6 translocation.
